Total infectomes of 162 SARS-CoV-2 cases using meta-transcriptomic sequencing

Total infectomes of 162 SARS-CoV-2 cases using meta-transcriptomic sequencing

Bibliographic Details
Main Authors:	Zhou, H, Li, C, Hu, T, Liu, T, Ni, N, Chen, W, Zhao, H, Ruan, S, Li, J, Wu, H, Pybus, OG, François, S, Holmes, EC, Kang, D, Hou, P, Shi, W
Format:	Journal article
Language:	English
Published:	Elsevier 2020

Similar Items

Skin infectome of patients with a tick bite history
by: Jie Zhang, et al.
Published: (2023-02-01)

Total Infectome Characterization of Respiratory Infections during the 2022–23 COVID-19 Outbreak in China Revealed Extensive Coinfections with Links to SARS-CoV-2 Status, Age, and Disease Severity
by: Zhongzhou Yang, et al.
Published: (2024-02-01)

Expanding the range of the respiratory infectome in Australian feedlot cattle with and without respiratory disease using metatranscriptomics
by: Barbara P. Brito, et al.
Published: (2023-07-01)

A Sequent of Gram-Negative Co-Infectome-Induced Acute Respiratory Distress Syndrome Are Potentially Subtle Aggravators Associated to the SARS-CoV-2 Evolution of Virulence
by: Kamaleldin B. Said, et al.
Published: (2024-01-01)

A viral-human interactome based on structural motif-domain interactions captures the human infectome.
by: Aldo Segura-Cabrera, et al.
Published: (2013-01-01)

Phylogenetic and phylodynamic approaches to understanding and combating the early SARS-CoV-2 pandemic
by: Attwood, SW, et al.
Published: (2022)

Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant
by: Li, B, et al.
Published: (2022)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
by: Jaime S. Rosa Duque, et al.
Published: (2022-08-01)

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
by: Yannic C. Bartsch, et al.
Published: (2022-12-01)

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents
by: Xiaofeng Mu, et al.
Published: (2022-12-01)

BNT162b2 Vaccination after SARS-CoV-2 Infection Changes the Dynamics of Total and Neutralizing Antibodies against SARS-CoV-2: A 6-Month Prospective Cohort Study
by: Jorge Hernández-Bello, et al.
Published: (2023-06-01)

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
by: Gian Luca Salvagno, et al.
Published: (2022-06-01)

Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
by: Lippi Giuseppe, et al.
Published: (2021-12-01)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
by: Tomer Hertz, et al.
Published: (2023-07-01)

162 Attitudes Toward the SARS-CoV-2 Vaccine in BIPOC Populations in Los Angeles County
by: Corey Jacinto, et al.
Published: (2022-04-01)

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
by: Saad-Roy, CH, et al.
Published: (2021)

Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis
by: Tingting Li, et al.
Published: (2022-01-01)

Serial interval distribution of SARS-CoV-2 infection in Brazil
by: Prete Jr, CA, et al.
Published: (2020)

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
by: Samuel M.S. Cheng, et al.
Published: (2024-03-01)

Sequence similarity of SARS-CoV-2 and humans: Implications for SARS-CoV-2 detection
by: Heng Li, et al.
Published: (2022-07-01)

Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients
by: Fabrizia Valleriani, et al.
Published: (2021-10-01)

Towards an understanding of the avian virome
by: François, S, et al.
Published: (2020)

Sequencing SARS-CoV-2 from antigen tests
by: Ashley Nazario-Toole, et al.
Published: (2022-01-01)

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
by: Nigam H. Padhiar, et al.
Published: (2022-05-01)

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
by: Mina Psichogiou, et al.
Published: (2021-09-01)

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
by: Nick K Jones, et al.
Published: (2021-04-01)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
by: Rune M. Pedersen, et al.
Published: (2022-06-01)

Viral and host small RNA transcriptome analysis of SARS-CoV-1 and SARS-CoV-2-infected human cells reveals novel viral short RNAs
by: Tom A.P. Driedonks, et al.
Published: (2024-02-01)

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
by: Dominique J. Barbeau, et al.
Published: (2022-07-01)

Transcriptome sequencing and SNP detection in Phoebe chekiangensis
by: Bing He, et al.
Published: (2017-05-01)

Genomic Analysis of the Suspicious SARS-CoV-2 Sequences in the Public Sequencing Database
by: Xiao Sun, et al.
Published: (2023-02-01)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
by: Carl Graham, et al.
Published: (2022-10-01)

Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children
by: Alessandra Ricciardi, et al.
Published: (2022-09-01)

Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2
by: Manca Ogrič, et al.
Published: (2022-12-01)

Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
by: Eleni Papadokostaki, et al.
Published: (2022-03-01)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
by: Jing Zou, et al.
Published: (2021-03-01)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
by: Michael Jahn, et al.
Published: (2021-04-01)

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population
by: Chloé Dimeglio, et al.
Published: (2023-06-01)

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
by: Angelos Hatzakis, et al.
Published: (2022-02-01)

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
by: Aharona Glatman-Freedman, et al.
Published: (2022-05-01)